This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
At the time, only Mike Piazza (35), David Justice (28), and Darryl Strawberry (26) had hit more home runs as an NL rookie since 1972, and only Piazza had more RBI (112). Helton finished second to Kerry Wood of the Chicago Cubs in the voting for NL Rookie of the Year. The Tennessee Sports Hall of Fame named Helton its 1998 Professional Athlete of the Year. In 1999, Helton put up a slash line of .320/.395/.587. He slugged 35 home runs and drove in 113 RBI, while also drawing 68 walks. On June 19, in a 10–2 home win over the Florida Marlins, Helton hit for the cycle. He fell one hit shy of hitting for a second cycle on four occasions during the 1999 season. Had he managed to repeat the performance that season, he would have become only the second player since 1900 to pull it off, the other being Babe Herman in 1931.
=== Birth rate === According to one report, in 1924, shortly after the Free State's establishment, the new dominion had the "lowest birth-rate in the world". The report noted that amongst countries for which statistics were available (Ceylon, Chile, Japan, Spain, South Africa, the Netherlands, Canada, Germany, Australia, the United States, Britain, New Zealand, Finland, and the Irish Free State), Ceylon had the highest birth rate at 40.8 per 1,000 while the Irish Free State had a birth rate of just 18.6 per 1,000.
In contrast to the elemental ions sodium, potassium, and calcium, there is no known cellular mechanism specifically dedicated to regulating intracellular lithium. Lithium can enter cells through epithelial sodium channels. Lithium ions interfere with ion transport processes (see "Sodium pump") that relay and amplify messages carried to the cells of the brain. Mania is associated with irregular increases in protein kinase C (PKC) activity within the brain. Lithium carbonate and sodium valproate, another drug conventionally used to treat the disorder, act in the brain by inhibiting PKC's activity and help to produce other compounds that also inhibit the PKC. Lithium carbonate's mood-controlling properties are not fully understood.
== Geography == According to the United States Census Bureau, the city has a total area of 149.60 square miles (387.5 km2), of which 148.54 sq mi (384.7 km2) is land and 1.07 sq mi (2.8 km2) (0.72%) is water. The Neuse River flows through the northeastern corner of the city. Raleigh is located in the northeast central region of North Carolina, where the Piedmont and Atlantic coastal plain regions meet. This area is known as the "fall line" because it marks the elevation inland at which waterfalls begin to appear in creeks and rivers. As a result, most of Raleigh features gently rolling hills that slope eastward toward the state's flat coastal plain. The city of Raleigh is located 24 mi (39 km) southeast of Durham; 63 mi (101 km) northeast of Fayetteville; 131 mi (211 km) northwest of Wilmington; 155 mi (249 km) southwest of Richmond, Virginia; and 165 mi (266 km) northeast of Charlotte. A small portion of Raleigh is located in Durham County, North Carolina.
Sources: en.wikipedia.org
=== Efficacy of abrocitinib in treating atopic dermatitis === According to the latest meta-analysis in 2023, abrocitinib is both efficient and safe in treating moderate-to-severe AD in adolescents and adults. It also relieves itching rapidly and alleviates symptoms of AD. Abrocitinib gives significantly better results than the placebo at both 100 mg and 200 mg. The severity of AD is quantified through Eczema Area and Severity Index (EASI), which is based on the severity of lesion clinical signs. Abrocitinib was more effective than placebo in terms of EASI-reduction, but it also decreased other symptoms. The improvement of depression and anxiety was better in the experimental group than that in the control group. In another meta-analysis including 2256 patients from three different studies have shown that abrocitinib improved the EASI scores in comparison with dupilumab, even in the second week of treatment. A faster onset of Investigator's Global Assessment (IGA) response at the second week was also achieved by administering abrocitinib and early relief of itching occurred at 2 weeks. In other studies, abrocitinib (200 mg dose) achieved rapid relief from itching after four days of treatment compared with dupilumab and placebo in AD patients.
=== Turnover and cell renewal === Cell division occurs predominantly in the basal layer, with cells migrating coronally and superficially. The turnover rate is slower than the junctional epithelium but faster than fully keratinized gingival epithelium.
Carey-Ann Burnham is a clinical microbiologist, and a professor of Pathology and Immunology, Molecular Microbiology, Pediatrics and Medicine in Washington University School of Medicine. She is an elected fellow of the American Society for Microbiology.
== Signs and symptoms == The most common sign of hypospermia is a low volume of semen during ejaculation. The diagnosis is confirmed when one has a semen volume of less than 2.0 mL on at least two successive spermograms. If hypospermia is caused by retrograde ejaculation, sign include cloudy urine after orgasm. There may not be any symptoms of hypospermia unless it is caused by an abnormality.
==== Other activities ==== Bicalutamide has been found to act as an inhibitor or inducer of certain cytochrome P450 enzymes including CYP3A4, CYP2C9, CYP2C19, and CYP2D6 in preclinical research, but no evidence of this has been found in humans treated with up to 150 mg/day. It has also been identified in vitro as a strong inhibitor of CYP27A1 (cholesterol 27-hydroxylase) and as an inhibitor of CYP46A1 (cholesterol 24-hydroxylase), but this has yet to be assessed or confirmed in vivo or in humans and the clinical significance remains unknown. Bicalutamide has been found to be a P-glycoprotein (ABCB1) inhibitor. Like other first-generation NSAAs and enzalutamide, it has been found to act as a weak non-competitive inhibitor of GABAA receptor-mediated currents in vitro (IC50 = 5.2 μM). However, unlike enzalutamide, bicalutamide has not been found to be associated with seizures or other related adverse central effects, so the clinical relevance of this finding is uncertain.
Sources: en.wikipedia.org
In May 2023, and with the dissolution of parliament amid the political crisis, he presented himself as a pre-candidate for the presidential elections of the same year, by the political movement National Democratic Action (ADN), and also supported by the movements People, Equality and Democracy (PID) and MOVER. His running mate was businesswoman Verónica Abad Rojas. His campaign has focused on job creation, tax incentives for newly established businesses and increased criminal sentences for tax evaders. He has also pledged to improve the justice system in the country amid growing violence. His campaign is seen as traditional, drawing on the Grupo Noboa social welfare foundation founded by his parents, as well as his ties as chairman of the Commission on Economic Development.
acidic type I hair keratin type I hair keratin 1, KRT31 type I hair keratin 2, KRT32 type I hair keratin 3A, KRT33A type I hair keratin 3B, KRT33B type I hair keratin 4, KRT34 type I hair keratin 5, KRT35 type I hair keratin 6, KRT36 type I hair keratin 7, KRT37 type I hair keratin 8, KRT38 basic type II hair keratin type II hair keratin 1, KRT81 type II hair keratin 2, KRT82 type II hair keratin 3, KRT83 type II hair keratin 4, KRT84 type II hair keratin 5, KRT85 type II hair keratin 6, KRT86
The Welsh Romance Peredur son of Efrawg is based on Chrétien or derived from a common original, but it contains several prominent deviations and lacks a Grail. The character of the Fisher King appears (though he is not called such) and presents Peredur with a severed head on a platter. Peredur later learns that he was related to that king, and that the severed head was that of his cousin, whose death he must avenge by defeating the Nine Witches.
The Ministry of Justice confirms that serial killer Levi Bellfield, who is serving two whole life sentences for murder, will be allowed to marry his girlfriend in prison as there are no legal restrictions preventing him from doing so. Boris Johnson breaks the Ministerial Code for a second time, by not asking advice from the Advisory Committee on Business Appointments before accepting a new job writing for the Daily Mail. The previous time was shortly after he stood down as foreign secretary in July 2018, when he accepted a similar job with the Daily Telegraph. A 31-year-old man is charged with three counts of murder and three of attempted murder following the Nottingham attacks. 17 June David Warburton, the MP for Somerton and Frome, becomes the fourth Conservative MP in eight days to announce their resignation from the House of Commons, doing so following his suspension from the party over allegations of sexual misconduct, and triggering a by-election in his constituency. The 2023 Trooping the Colour ceremony takes place. 18 June – Partygate: The Mirror publishes video footage of a party held in December 2020 at Conservative Party Headquarters. Housing Secretary Michael Gove describes the incident as "indefensible". 19 June – Partygate: MPs back, by 354 votes to seven, a report finding Boris Johnson deliberately misled the Commons over lockdown parties at Downing Street. 20 June The Chancellor, Jeremy Hunt, rules out direct financial support for mortgage holders, over fears it would "make inflation worse, not better".
=== Post-translational modifications === Most programs available for protein analysis are not written for proteins that have undergone post-translational modifications. Some programs will accept post-translational modifications to aid in protein identification but then ignore the modification during further protein analysis. It is important to account for these modifications since they can affect the protein's structure. In turn, computational analysis of post-translational modifications has gained the attention of the scientific community. The current post-translational modification programs are only predictive. Chemists, biologists and computer scientists are working together to create and introduce new pipelines that allow for analysis of post-translational modifications that have been experimentally identified for their effect on the protein's structure and function.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.